US-based Rutgers University biorepository unit RUCDR Infinite Biologics has added NuGEN Technologies to its technology sponsors group to act as its corporate sponsor and genomic processing partner.
Currently having more than 12 million biosamples in its repository, RUCDR helps researchers worldwide through provision of biomaterials, technical consultation and logistic support. It also plays an important in finding the genetic causes of common diseases.
RUCDR Infinite Biologics chief operating officer Andy Brooks said that the RUCDR corporate sponsorship program is the cornerstone of the relationship with their most valued technology suppliers.
"It enables us to align the activities of our partners with the strategic goals of RUCDR and to offer the most competitive and cutting-edge services to our pharmaceutical, diagnostic, and clinical research customers worldwide," Brooks added.
NuGEN Technologies chief executive officer Elizabeth Hutt said, "The partnership has given us a unique insight into the needs of scientists working in clinical research and routine clinical testing."
Besides, both firms are working collaboratively on several projects, including sample preparation methods for RNA-seq analysis of single cells and rapid and convenient target enrichment technology for NGS analysis.
